These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 18990961)

  • 21. Macrolides as immunomodulatory medications for the therapy of chronic lung diseases.
    López-Boado YS; Rubin BK
    Curr Opin Pharmacol; 2008 Jun; 8(3):286-91. PubMed ID: 18339582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibiotic therapy for exacerbations of chronic obstructive pulmonary disease (COPD).
    Butorac-Petanjek B; Parnham MJ; Popovic-Grle S
    J Chemother; 2010 Oct; 22(5):291-7. PubMed ID: 21123150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Long-term macrolide treatment in adult chronic bronchial diseases: benefits and limits].
    Jouneau S; Desrues B
    Presse Med; 2014 May; 43(5):510-9. PubMed ID: 24631048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.
    Zarogoulidis P; Papanas N; Kioumis I; Chatzaki E; Maltezos E; Zarogoulidis K
    Eur J Clin Pharmacol; 2012 May; 68(5):479-503. PubMed ID: 22105373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?
    Amsden GW
    J Antimicrob Chemother; 2005 Jan; 55(1):10-21. PubMed ID: 15590715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-inflammatory effects of macrolides in lung disease.
    Jaffé A; Bush A
    Pediatr Pulmonol; 2001 Jun; 31(6):464-73. PubMed ID: 11389580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Azithromycin during Acute Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization (BACE). A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial.
    Vermeersch K; Gabrovska M; Aumann J; Demedts IK; Corhay JL; Marchand E; Slabbynck H; Haenebalcke C; Haerens M; Hanon S; Jordens P; Peché R; Fremault A; Lauwerier T; Delporte A; Vandenberk B; Willems R; Everaerts S; Belmans A; Bogaerts K; Verleden GM; Troosters T; Ninane V; Brusselle GG; Janssens W
    Am J Respir Crit Care Med; 2019 Oct; 200(7):857-868. PubMed ID: 31046405
    [No Abstract]   [Full Text] [Related]  

  • 28. Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments.
    Cameron EJ; McSharry C; Chaudhuri R; Farrow S; Thomson NC
    Clin Exp Allergy; 2012 Sep; 42(9):1302-12. PubMed ID: 22925316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Macrolide antibiotics, bacterial populations and inflammatory airway disease.
    Swords WE; Rubin BK
    Neth J Med; 2003 Jul; 61(7):242-8. PubMed ID: 14567521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolonged treatment with macrolides in adult patients with non-cystic fibrosis bronchiectasis: meta-analysis of randomized controlled trials.
    Zhuo GY; He Q; Xiang-Lian L; Ya-Nan Y; Si-Te F
    Pulm Pharmacol Ther; 2014 Oct; 29(1):80-8. PubMed ID: 24594263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis.
    Schultz MJ
    J Antimicrob Chemother; 2004 Jul; 54(1):21-8. PubMed ID: 15190022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Azithromycin or erythromycin? Macrolides for non-cystic fibrosis bronchiectasis in adults: A systematic review and adjusted indirect treatment comparison.
    Li W; Qin Z; Gao J; Jiang Z; Chai Y; Guan L; Chen Y
    Chron Respir Dis; 2019; 16():1479972318790269. PubMed ID: 30101613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapeutic efficacy of macrolide anti-infective agents and other pharmacological actions].
    Azuma A
    Nihon Naika Gakkai Zasshi; 2005 Feb; 94(2):376-85. PubMed ID: 15768605
    [No Abstract]   [Full Text] [Related]  

  • 34. Meta-analysis of macrolide maintenance therapy for prevention of disease exacerbations in patients with noncystic fibrosis bronchiectasis.
    Wang D; Fu W; Dai J
    Medicine (Baltimore); 2019 Apr; 98(17):e15285. PubMed ID: 31027086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunomodulatory activity and effectiveness of macrolides in chronic airway disease.
    Rubin BK; Henke MO
    Chest; 2004 Feb; 125(2 Suppl):70S-78S. PubMed ID: 14872003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The immunomodulatory effects of macrolide antibiotics in respiratory disease.
    Pollock J; Chalmers JD
    Pulm Pharmacol Ther; 2021 Dec; 71():102095. PubMed ID: 34740749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of atypical infections and macrolide therapy in patients with asthma.
    Rollins DR; Good JT; Martin RJ
    J Allergy Clin Immunol Pract; 2014; 2(5):511-7. PubMed ID: 25213043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Past, present and future of macrolide therapy for chronic rhinosinusitis in Japan.
    Shimizu T; Suzaki H
    Auris Nasus Larynx; 2016 Apr; 43(2):131-6. PubMed ID: 26441370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulatory effects of macrolides on bacterial virulence: potential role as quorum-sensing inhibitors.
    Tateda K; Standiford TJ; Pechere JC; Yamaguchi K
    Curr Pharm Des; 2004; 10(25):3055-65. PubMed ID: 15544497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases.
    Serisier DJ
    Lancet Respir Med; 2013 May; 1(3):262-74. PubMed ID: 24429132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.